Research programme: cell based therapeutics - Endonovo Therapeutics

Drug Profile

Research programme: cell based therapeutics - Endonovo Therapeutics

Latest Information Update: 16 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Aeronautics and Space Administration
  • Developer Endonovo Therapeutics
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Graft-versus-host disease

Most Recent Events

  • 10 Aug 2016 Endonovo files for patent protection with United States patent and Trademark Office (USPTO) for production of biologics for treating chemical and radiation injuries in USA
  • 10 Aug 2016 Endonovo has patent protection for "Use of electromagnetic stimulation of cells to produce biological molecules" in USA
  • 29 Jun 2016 Endonovo Therapeutics files for continuation patent protection for production of the adult stem cell secretome in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top